Reinhard Dummer1, Dirk Schadendorf2, Paolo A Ascierto3, Ana Arance4, Caroline Dutriaux5, Anna Maria Di Giacomo6, Piotr Rutkowski7, Michele Del Vecchio8, Ralf Gutzmer9, Mario Mandala10, Luc Thomas11, Lev Demidov12, Claus Garbe13, David Hogg14, Gabriella Liszkay15, Paola Queirolo16, Ernesto Wasserman17, James Ford17, Marine Weill18, L Andres Sirulnik17, Valentine Jehl18, Viviana Bozón19, Georgina V Long20, Keith Flaherty21. 1. Department of Dermatology, University Hospital Zürich Skin Cancer Center, Zürich, Switzerland. Electronic address: reinhard.dummer@usz.ch. 2. Department of Dermatology, University Hospital Essen, Essen, Germany; German Cancer Consortium, Heidelberg, Germany. 3. Melanoma Unit, Cancer Immunotherapy and Innovative Therapies, Istituto Nazionale Tumori Fondazione Pascale, Via Mariano Semmola, Naples, Italy. 4. Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain. 5. Department of Oncologic Dermatology, Centre Hospitalier Universitaire de Bordeaux, Hôpital Saint-André, Bordeaux, France. 6. Medical Oncology and Immunotherapy, University Hospital of Siena, Viale Bracci, Siena, Italy. 7. Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland. 8. Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Giacomo Venezian, Milan, Italy. 9. Department of Dermatology and Allergy, Skin Cancer Center Hannover, Hannover Medical School, Hannover, Germany. 10. Department of Oncology and Haematology, Papa Giovanni XXIII Cancer Center Hospital, Bergamo, Italy. 11. Department of Dermatology, Centre Hospitalier Lyon Sud, Lyons Cancer Research Center, Lyon 1 University, Pierre Bénite, France. 12. N N Blokhin Russian Cancer Research Center, Ministry of Health, Moscow, Russian Federation. 13. Department of Dermatology, University Hospital Tuebingen, Tuebingen, Germany. 14. Department of Medicine, University Health Network/Princess Margaret Hospital, Toronto, ON, Canada. 15. Department of Dermatology, National Institute of Oncology, Budapest, Hungary. 16. Department of Medical Oncology, Institute for Cancer Research, IRCCS San Martino, Largo Rosanna Benzi, Genova, Italy. 17. Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, NJ, USA. 18. Novartis Pharma AG, Basel, Switzerland. 19. Array BioPharma, Boulder, CO, USA. 20. Melanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospitals, Sydney, NSW, Australia. 21. Department of Medical Oncology, Massachusetts General Hospital, Boston, MA, USA.
Abstract
BACKGROUND: There are no established therapies specific for NRAS-mutant melanoma despite the emergence of immunotherapy. We aimed to assess the efficacy and safety of the MEK inhibitor binimetinib versus that of dacarbazine in patients with advanced NRAS-mutant melanoma. METHODS:NEMO is an ongoing, randomised, open-label phase 3 study done at 118 hospitals in 26 countries. Patients with advanced, unresectable, American Joint Committee on Cancer stage IIIC or stage IV NRAS-mutant melanoma who were previously untreated or had progressed on or after previous immunotherapy were randomised (2:1) to receive either binimetinib 45 mg orally twice daily or dacarbazine 1000 mg/m2 intravenously every 3 weeks. Randomisation was stratified by stage, performance status, and previous immunotherapy. The primary endpoint was progression-free survival assessed by blinded central review in the intention-to-treat population. Safety analyses were done in the safety population, consisting of all patients who received at least one study drug dose and one post-baseline safety assessment. This study is registered with ClinicalTrials.gov, number NCT01763164 and with EudraCT, number 2012-003593-51. FINDINGS:Between Aug 19, 2013, and April 28, 2015, 402 patients were enrolled and randomly assigned, 269 to binimetinib and 133 todacarbazine. Median follow-up was 1·7 months (IQR 1·4-4·1). Median progression-free survival was 2·8 months (95% CI 2·8-3·6) in the binimetinib group and 1·5 months (1·5-1·7) in the dacarbazine group (hazard ratio 0·62 [95% CI 0·47-0·80]; one-sided p<0·001). Grade 3-4 adverse events seen in at least 5% of patients the safety population in either group were increased creatine phosphokinase (52 [19%] of 269 patients in the binimetinib group vs none of 114 in the dacarbazine group), hypertension (20 [7%] vs two [2%]), anaemia (five [2%] vs six [5%]), and neutropenia (two [1%] vs ten [9%]). Serious adverse events (all grades) occurred in 91 (34%) patients in the binimetinib group and 25 (22%) patients in the dacarbazine group. INTERPRETATION: Binimetinib improved progression-free survival compared with dacarbazine and was tolerable. Binimetinib might represent a new treatment option for patients with NRAS-mutant melanoma after failure of immunotherapy. FUNDING: Array BioPharma and Novartis Pharmaceuticals Corporation.
RCT Entities:
BACKGROUND: There are no established therapies specific for NRAS-mutant melanoma despite the emergence of immunotherapy. We aimed to assess the efficacy and safety of the MEK inhibitor binimetinib versus that of dacarbazine in patients with advanced NRAS-mutant melanoma. METHODS:NEMO is an ongoing, randomised, open-label phase 3 study done at 118 hospitals in 26 countries. Patients with advanced, unresectable, American Joint Committee on Cancer stage IIIC or stage IV NRAS-mutant melanoma who were previously untreated or had progressed on or after previous immunotherapy were randomised (2:1) to receive either binimetinib 45 mg orally twice daily or dacarbazine 1000 mg/m2 intravenously every 3 weeks. Randomisation was stratified by stage, performance status, and previous immunotherapy. The primary endpoint was progression-free survival assessed by blinded central review in the intention-to-treat population. Safety analyses were done in the safety population, consisting of all patients who received at least one study drug dose and one post-baseline safety assessment. This study is registered with ClinicalTrials.gov, number NCT01763164 and with EudraCT, number 2012-003593-51. FINDINGS: Between Aug 19, 2013, and April 28, 2015, 402 patients were enrolled and randomly assigned, 269 to binimetinib and 133 to dacarbazine. Median follow-up was 1·7 months (IQR 1·4-4·1). Median progression-free survival was 2·8 months (95% CI 2·8-3·6) in the binimetinib group and 1·5 months (1·5-1·7) in the dacarbazine group (hazard ratio 0·62 [95% CI 0·47-0·80]; one-sided p<0·001). Grade 3-4 adverse events seen in at least 5% of patients the safety population in either group were increased creatine phosphokinase (52 [19%] of 269 patients in the binimetinib group vs none of 114 in the dacarbazine group), hypertension (20 [7%] vs two [2%]), anaemia (five [2%] vs six [5%]), and neutropenia (two [1%] vs ten [9%]). Serious adverse events (all grades) occurred in 91 (34%) patients in the binimetinib group and 25 (22%) patients in the dacarbazine group. INTERPRETATION:Binimetinib improved progression-free survival compared with dacarbazine and was tolerable. Binimetinib might represent a new treatment option for patients with NRAS-mutant melanoma after failure of immunotherapy. FUNDING: Array BioPharma and Novartis Pharmaceuticals Corporation.
Authors: Jasmine H Francis; Larissa A Habib; David H Abramson; Lawrence A Yannuzzi; Murk Heinemann; Mrinal M Gounder; Rachel N Grisham; Michael A Postow; Alexander N Shoushtari; Ping Chi; Neil H Segal; Rona Yaeger; Alan L Ho; Paul B Chapman; Federica Catalanotti Journal: Ophthalmology Date: 2017-07-12 Impact factor: 12.079
Authors: Claudia Capparelli; Timothy J Purwin; Shea A Heilman; Inna Chervoneva; Peter A McCue; Adam C Berger; Michael A Davies; Jeffrey E Gershenwald; Clemens Krepler; Andrew E Aplin Journal: Cancer Res Date: 2018-08-16 Impact factor: 12.701
Authors: Nayan Lamba; Rachel Brigell Kearney; Paul J Catalano; Michael J Hassett; Patrick Y Wen; Daphne A Haas-Kogan; Ayal A Aizer Journal: Neuro Oncol Date: 2021-04-12 Impact factor: 12.300
Authors: Wafik S El-Deiry; Richard M Goldberg; Heinz-Josef Lenz; Anthony F Shields; Geoffrey T Gibney; Antoinette R Tan; Jubilee Brown; Burton Eisenberg; Elisabeth I Heath; Surasak Phuphanich; Edward Kim; Andrew J Brenner; John L Marshall Journal: CA Cancer J Clin Date: 2019-05-22 Impact factor: 508.702
Authors: Paolo A Ascierto; Sanjiv S Agarwala; Gennaro Ciliberto; Sandra Demaria; Reinhard Dummer; Connie P M Duong; Soldano Ferrone; Silvia C Formenti; Claus Garbe; Ruth Halaban; Samir Khleif; Jason J Luke; Lluis M Mir; Willem W Overwijk; Michael Postow; Igor Puzanov; Paul Sondel; Janis M Taube; Per Thor Straten; David F Stroncek; Jennifer A Wargo; Hassane Zarour; Magdalena Thurin Journal: J Transl Med Date: 2017-11-16 Impact factor: 5.531
Authors: Heike Niessner; Tobias Sinnberg; Corinna Kosnopfel; Keiran S M Smalley; Daniela Beck; Christian Praetorius; Marion Mai; Stefan Beissert; Dagmar Kulms; Martin Schaller; Claus Garbe; Keith T Flaherty; Dana Westphal; Ines Wanke; Friedegund Meier Journal: Clin Cancer Res Date: 2017-07-19 Impact factor: 12.531